Clenbuterol

Amyotrophic Lateral Sclerosis

Dwight Koeberl, M.D., Ph.D.Small moleculePhase 2Dormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 73/ 100

Competitive context

151 Active assets in the Amyotrophic Lateral Sclerosis cohort.

Asset / Sponsor	Phase	Rating
TAURURSODIOL Amylyx Pharmaceuticals Inc.	Phase 3	BBB
Tofersen Biogen	Phase 4	BBB
Mexiletine Bjorn Oskarsson, MD	Phase 4	BB
Riluzole AB Science	Phase 4	BB
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II) Collaborative Medicinal Development Pty Limited	Phase 2/3	BB

View all 50 →

Same molecule, other indications

Clenbuterol is also rated in:

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease DementiaDormant

B

Indicative ·

57 / 100

type 2 diabetes mellitusDormant

CCC

Indicative ·

54 / 100

glycogen storage disease due to acid maltase deficiency, late-onsetDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.